Tariq Naima, Dani Shefali, Makhija Purnima, Warren Madhuri V
Department of Cellular Pathology, Royal London Hospital, Bart's Health NHS Trust, London, E1 2ES, UK.
Department of Cellular Pathology, Queen's Hospital, Barking, Haveridge & Redbridge University Hospitals NHS Trust, Romford, London, RM7 0AG, UK.
Breast Cancer Res Treat. 2025 Apr;210(2):393-404. doi: 10.1007/s10549-024-07577-3. Epub 2024 Dec 12.
Breast hamartomas are rarely associated with epithelial atypia or malignancy. Since the introduction of digital mammography in the UK from 2008, hamartoma detection has increased. The aim of this study was to identify if there are characteristic clinical, radiological or histological features that distinguish hamartomas with intralesional atypia/malignancy (complex hamartomas, CH) or ipsilateral/contralateral atypia/malignancy (non-CH) from those without atypia/malignancy at diagnosis (other benign hamartomas, BH).
We performed a retrospective single-institution review of 450 hamartomas reported between 2010 and 2023. Anonymised H&E sections and imaging of CH and non-CH were reviewed to identify distinguishing features.
13,441 benign breast lesions were biopsied/resected between 2010 and 2023 including 450 hamartomas (3.3%), 19 of which (4.2%) were associated with atypia or malignancy. 14 were analysed further (7 CH; 7 non-CH). The mean age of CH plus non-CH patients was significantly higher than patients with BH (47.5 vs. 40.6 years; p = 0.03). The mean size of CH was greater than non-CH (32.1 mm vs.17.6 mm; p = 0.06). There was a statistically significantly higher incidence of atypical/malignant lobular lesions (ALH/LCIS/ILC) in CH vs. non-CH (42.9% vs 0%; p = 0.05). MRI was performed in 2 CH and 3 non-CH; in all 5 the associated malignancy was detected. There was no significant difference between the CH and non-CH group in ultrasound/mammographic features, other hamartoma histological features or other associated benign breast changes.
Ultrasound/mammogram are not sufficiently sensitive to identify hamartomas with associated atypia/malignancy. Certain hamartoma features may preferentially be associated with atypia/malignancy and which merit further radiological and/or detailed histological investigation.
乳腺错构瘤很少与上皮异型性或恶性肿瘤相关。自2008年数字乳腺摄影在英国引入以来,错构瘤的检出率有所增加。本研究的目的是确定是否存在特征性的临床、放射学或组织学特征,以区分诊断时伴有瘤内异型性/恶性肿瘤(复杂性错构瘤,CH)或同侧/对侧异型性/恶性肿瘤(非CH)的错构瘤与无异型性/恶性肿瘤的错构瘤(其他良性错构瘤,BH)。
我们对2010年至2023年期间报告的450例错构瘤进行了单机构回顾性研究。对CH和非CH的匿名苏木精-伊红切片及影像学检查进行回顾,以确定鉴别特征。
2010年至2023年期间,13441例良性乳腺病变接受了活检/手术切除,其中包括450例错构瘤(3.3%),其中19例(4.2%)与异型性或恶性肿瘤相关。对14例进行了进一步分析(7例CH;7例非CH)。CH加非CH患者的平均年龄显著高于BH患者(47.5岁对40.6岁;p = 0.03)。CH的平均大小大于非CH(32.1mm对17.6mm;p = 0.06)。CH中不典型/恶性小叶病变(ALH/LCIS/ILC)的发生率在统计学上显著高于非CH(42.9%对0%;p = 0.05)。2例CH和3例非CH进行了MRI检查;在所有5例中均检测到相关恶性肿瘤。CH组和非CH组在超声/乳腺摄影特征、其他错构瘤组织学特征或其他相关良性乳腺改变方面无显著差异。
超声/乳腺摄影对识别伴有异型性/恶性肿瘤的错构瘤不够敏感。某些错构瘤特征可能优先与异型性/恶性肿瘤相关,值得进一步进行放射学和/或详细的组织学研究。